<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01165970</url>
  </required_header>
  <id_info>
    <org_study_id>T-01/2008-005451-23</org_study_id>
    <secondary_id>2008-005451-23</secondary_id>
    <nct_id>NCT01165970</nct_id>
  </id_info>
  <brief_title>Effect of Saliva Substitutes on Dental Hard Tissues in Situ</brief_title>
  <acronym>T-01</acronym>
  <official_title>Vergleichende, Randomisierte, Kontrollierte Und Doppelblinde In-situ-Studie Zur Wirkung Von Speichelersatzmitteln Auf Schmelz Und Dentin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Symptomatic hyposalivation is associated not only with Sjögren`s syndrome or salivary gland
      hypofunction in elderly patients, but also with medications containing antimuscarinic drugs,
      chemo radiotherapy for head and neck carcinomas, and psychiatric disorders (Atkinson &amp; Ava,
      1994, Kielbassa et al., 2006).

      Human saliva possesses important physiological functions in protecting and moistening the
      oral hard and soft tissues (Piotrowski et al., 1992, ). Consequently, decreasing salivation
      causes oral dysfunction and promotes severe oral side effects (reduced antibacterial
      function, lack of remineralisation, reduced buffer capacity) (Tschoppe et al., 2010a). These
      have been identified as being responsible for the rapid destruction of the dentition (Willich
      et al., 1988). Saliva substitutes are frequently applied for relieving the symptoms in
      patients suffering from hyposalivation (Hahnel et al., 2009, Nieuw Amerongen &amp; Veerman, 2003,
      Vissink et al., 2004). Besides the moistening and lubrication of the oral mucosa, these
      products should also protect dental hard tissues. However, in vitro studies revealed that
      some marketed products have only a neutral or even a demineralising potential on enamel as
      well as on dentin (Kielbassa et al., 2001, Meyer-Lueckel et al., 2002, Smith et al., 2001,
      Tschoppe et al., 2009). Inorganic ions such as calcium, phosphates, and fluorides have been
      added to saliva substitutes in order to enhance their remineralising property or minimize
      their demineralising potential (Tschoppe et al., 2009). Furthermore, as most patients
      suffering from hyposalivation are elderly people, recessions and subsequently exposed dentin
      surfaces are very common. Since dentin is not as acid resistant as enamel, an earlier and
      more severe demineralisation can be expected (Saunders &amp; Meyerowitz, 2005).

      Therefore, the current in situ study was performed to assess the effects of a demineralising
      and a remineralising saliva substitutes on the mineralisation of dental hard tissues. It was
      hypothesized that storage in Glandosane(cell pharm, Hannover, Germany) would not result in
      pronounced mineral loss of dentin specimens, and that storage in Saliva natura would not
      result in enhanced remineralisation when combined with a remineralising artificial saliva
      (Saliva natura supersaturated with respect to relevant calcium phosphates; medac, Hamburg,
      Germany) (H0). These null hypotheses were tested against the alternative hypothesis of a
      difference.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      see application for the German Federal Institute for Drugs and Medical Devices at Eudra-CT
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">March 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mineral loss and lesion depth of specimens</measure>
    <time_frame>15 weeks</time_frame>
    <description>Evaluation of the mineral loss/lesion depth of the enamel and dentin specimens after in situ exposition evaluated with transversal microradiography. The Unit is the mineral oss as well as lesion depth.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>general and oral well being</measure>
    <time_frame>15 weeks</time_frame>
    <description>Evaluation of the general and oral well being before and after therapy by questionnaires.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Hyposalivation</condition>
  <arm_group>
    <arm_group_label>Glandosane</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After in situ exposition the enamel and dentin samples will demineralize with Glandosane.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saliva natura</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After in situ exposition the enamel and dentin samples will remineralize with Saliva natura</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glandosane</intervention_name>
    <description>according to the german law the sued saliva substitute is a drug (Glandosane) whereas Saliva natura is a medical product</description>
    <arm_group_label>Glandosane</arm_group_label>
    <other_name>Glandosane, Cell Pharm, Germany</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Saliva natura</intervention_name>
    <description>Saliva substitute without restriction to be used</description>
    <arm_group_label>Saliva natura</arm_group_label>
    <other_name>Saliva natura, Medac, Germany</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  stimulated salivary flow rate &lt; 0.5 ml/min

          -  partial denture upper or lower jaw

          -  radiationtherapy in the head and neck area

          -  patient age above 18 years

          -  Signed informed consent (AMG §40 (1) 3b)

        Exclusion Criteria:

          -  stimulated salivary flow rate &gt; 0.5 ml/min

          -  missing partial denture upper or lower jaw

          -  missing Radiationtherapy in the head and neck area

          -  paraben allergy

          -  not signed informed consent (AMG §40 (1) 3b)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Tschoppe, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Operative Dentistry and Periodontology, School of Dental Medicine, CharitéCentrum 3, Charité - Universitätsmedizin Berlin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charite, Berlin, Germany</name>
      <address>
        <city>Berlin</city>
        <zip>14197</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>14197</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://kons-paro.charite.de</url>
    <description>please check the science subsite</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/20305867</url>
    <description>Short review on the main problems in this patient population: Etiologic factors of hyposalivation and consequences for oral health. Quintessence Int. 2010 Apr;41(4):321-33. Review.</description>
  </link>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2010</study_first_submitted>
  <study_first_submitted_qc>July 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2010</study_first_posted>
  <last_update_submitted>November 12, 2011</last_update_submitted>
  <last_update_submitted_qc>November 12, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 15, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Peter Tschoppe</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>enamel</keyword>
  <keyword>dentin</keyword>
  <keyword>saliva substitute</keyword>
  <keyword>demineralization</keyword>
  <keyword>remineralization</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

